Dole plc Reports Third Quarter 2022 Financial Results
Dole plc (NYSE: DOLE) reported Q3 2022 revenue of $2.3 billion, up from $1.9 billion last year, driven by the acquisition of Dole Food Company. Net income reached $46.6 million with a diluted EPS of $0.42, significantly improving from a loss of $0.35 in Q3 2021. Adjusted EBITDA was $73.0 million, reflecting a 25.7% increase on a pro-forma basis. Despite this, pro-forma revenue decreased by 1.7% due to foreign currency effects. Dole maintains a lower-end guidance for Adjusted EBITDA for the fiscal year.
- Q3 2022 revenue increased to $2.3 billion from $1.9 billion.
- Net income rose to $46.6 million, compared to a loss of $21.6 million last year.
- Diluted EPS improved to $0.42 from a negative $0.35 in Q3 2021.
- Adjusted EBITDA increased to $73.0 million, up 25.7% on a pro-forma basis.
- Fresh Fruit sales increased by 11.7%, driven by higher banana prices.
- Pro-forma revenue decreased by 1.7%, or $38.5 million, due to negative currency translation.
- Diversified Fresh Produce - EMEA saw a revenue drop of 13.4%, primarily from currency translation.
- Fresh Vegetables revenue declined by 5.2% due to lower volumes of value-added salads.
Highlights for the three months ended
-
Revenue of
$2.3 billion -
Net Income of
and Diluted EPS of$46.6 million $0.42 -
Adjusted EBITDA1 of
$73.0 million -
Adjusted Net Income1 of
and Adjusted Diluted EPS1 of$13.5 million $0.14
Financial Highlights - Unaudited
Three Months Ended |
|||
|
|
|
|
Revenue - $’m |
2,268 |
1,942 |
2,306 |
Net Income - $'m |
46.6 |
(21.6) |
35.9 |
Net Income attributable to |
39.8 |
(28.5) |
28.6 |
Diluted EPS - $ |
0.42 |
(0.35) |
0.30 |
Adjusted EBITDA - $’m1 |
73.0 |
54.9 |
58.1 |
Adjusted Net Income - $’m1 |
13.5 |
6.0 |
2.4 |
Adjusted Diluted EPS - $1 |
0.14 |
0.07 |
0.03 |
Nine Months Ended |
|||
|
|
|
|
Revenue - $’m |
6,873 |
4,203 |
7,034 |
Net Income - $'m |
98.4 |
41.4 |
177.1 |
Net Income attributable to |
79.7 |
22.0 |
155.8 |
Diluted EPS - $ |
0.84 |
0.34 |
1.64 |
Adjusted EBITDA - $’m1 |
263.3 |
229.0 |
332.5 |
Adjusted Net Income - $’m1 |
83.0 |
73.1 |
127.7 |
Adjusted Diluted EPS - $1 |
0.87 |
1.13 |
1.34 |
__________________________________________ | ||
1 |
|
|
2 |
This press release contains pro-forma financial information. The unaudited pro-forma consolidated financial statements for |
Commenting on the results,
“We are pleased with the strong results delivered for the third quarter of 2022, which were significantly ahead of the prior year and ahead of our own expectations. The broad diversification of our product offering, and the wide geographic footprint of our vertically integrated business provides us with a strong foundation for continued growth.
As we move towards the end of the financial year, we are now targeting Adjusted EBITDA within our previously guided range but at the lower end.
Our talented and dedicated people are our greatest asset, and we thank them for their significant contributions during the past year.”
Revenue for the three months ended
Adjusted EBITDA for the three months ended
Adjusted Net Income for the three months ended
__________________________________________ | ||
3 |
Like-for-like basis refers to the measure excluding the impact of foreign currency translation movements and acquisitions and divestitures. |
Selected Segmental Financial Information (Unaudited)
Three Months Ended |
|||||||||||||||
|
Pro-forma |
||||||||||||||
( |
|||||||||||||||
|
Revenue |
|
Adjusted EBITDA |
|
Revenue |
|
Adjusted EBITDA |
||||||||
Fresh Fruit |
$ |
751,348 |
|
$ |
51,076 |
|
$ |
672,737 |
|
$ |
16,994 |
||||
|
|
759,964 |
|
|
31,616 |
|
|
877,423 |
|
|
35,851 |
||||
|
|
479,839 |
|
|
(725 |
) |
|
453,704 |
|
|
4,280 |
||||
Fresh Vegetables |
|
306,843 |
|
|
(8,987 |
) |
|
323,772 |
|
|
925 |
||||
Intersegment |
|
(30,456 |
) |
|
— |
|
|
(21,599 |
) |
|
— |
||||
Total |
$ |
2,267,538 |
|
$ |
72,980 |
|
$ |
2,306,037 |
|
$ |
58,050 |
Nine Months Ended |
|||||||||||||||
|
|
||||||||||||||
( |
|||||||||||||||
|
Revenue |
Adjusted EBITDA |
Revenue |
Adjusted EBITDA |
|||||||||||
Fresh Fruit |
$ |
2,306,982 |
|
$ |
170,942 |
|
$ |
2,196,149 |
|
$ |
194,307 |
||||
|
|
2,400,967 |
|
|
91,088 |
|
|
2,623,011 |
|
|
101,762 |
||||
|
|
1,391,731 |
|
|
28,720 |
|
|
1,299,363 |
|
|
32,494 |
||||
Fresh Vegetables |
|
890,820 |
|
|
(27,420 |
) |
|
983,746 |
|
|
3,906 |
||||
Intersegment |
|
(117,845 |
) |
|
— |
|
|
(68,077 |
) |
|
— |
||||
Total |
$ |
6,872,655 |
|
$ |
263,330 |
|
$ |
7,034,192 |
|
$ |
332,469 |
Fresh Fruit
Revenue for the three months ended
Adjusted EBITDA for the three months ended
Revenue for the three months ended
Adjusted EBITDA for the three months ended
Revenue for the three months ended
Adjusted EBITDA for the three months ended
Fresh Vegetables
Revenue for the three months ended
Adjusted EBITDA for the three months ended
Capital Expenditures
Capital expenditures for the nine months ended
Net Debt
Net Debt as of
Outlook for Fiscal Year 2022 (forward-looking statement)
For fiscal year 2022, Dole is targeting:
-
Revenue in the range of
to$9.1 billion $9.4 billion -
Adjusted EBITDA at the lower end of the range of
to$330.0 million $350.0 million -
Capital Expenditures of approximately
(reflects a reduction from$95.0 million )$110.0 million -
Interest Expense of approximately
$60.0 million -
Adjusted Effective tax rate in the range of
23% to25%
The global economic environment remains dynamic, and we are currently seeing positive trends, along with some further challenges, as we progress through the final quarter of this financial year. Our focus remains on delivering operating efficiencies and being disciplined in our deployment of capital, while continuing to push for inflation-justified price increases. Our scale and wide geographic footprint, along with our diverse portfolio of healthy and nutritious products, leaves us well positioned as we move towards 2023.
For the full year, we now expect Adjusted EBITDA to be at the lower end of our previously guided range due to the ongoing challenges within our Fresh Vegetables segment, which has taken longer in its recovery, as well as the impact of the unusual supply chain challenges encountered in the third quarter at the end of the Chilean grape season in
The above outlook includes non-GAAP financial measures. Please refer to the appendix of this release for an explanation and reconciliation of our historical non-GAAP financial measures used in this release to comparable GAAP financial measures.
Dividend
On
About
A global leader in fresh produce,
Webcast and Conference Call Information
An archived replay of the webcast will also be available shortly after the live event has concluded. The conference call can be accessed live by dialing +1 646 664 1960 in the
A replay of the call will be available through
Forward-looking information
Certain statements made in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s beliefs, assumptions, and expectations of our future economic performance, considering the information currently available to management. These statements are not statements of historical fact. The words “believe,” “may,” “could,” “will,” “should,” “would,” “anticipate,” “estimate,” “expect,” “intend,” “objective,” “seek,” “strive,” “target” or similar words, or the negative of these words, identify forward-looking statements. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates, or expectations contemplated by us will be achieved. Such forward-looking statements are subject to various risks and uncertainties and assumptions relating to our operations, financial results, financial condition, business prospects, growth strategy and liquidity. Accordingly, there are, or will be, important factors that could cause our actual results to differ materially from those indicated in these statements. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, our actual results may vary materially from what we may have expressed or implied by these forward-looking statements. We caution that you should not place undue reliance on any of our forward-looking statements. Any forward-looking statement speaks only as of the date on which such statement is made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made except as required by the federal securities laws.
Appendix |
||||||||||||
Consolidated Statement of Operations - Unaudited |
||||||||||||
Three Months Ended |
||||||||||||
|
|
|
||||||||||
Pro-forma |
||||||||||||
( |
||||||||||||
Revenues, net |
$ |
2,267,538 |
|
$ |
1,942,185 |
|
$ |
2,306,037 |
|
|||
Cost of sales |
|
(2,134,062 |
) |
|
(1,843,415 |
) |
|
(2,168,311 |
) |
|||
Gross profit |
|
133,476 |
|
|
98,770 |
|
|
137,726 |
|
|||
Selling, marketing, general and administrative expenses |
|
(116,326 |
) |
|
(110,213 |
) |
|
(121,698 |
) |
|||
Merger, transaction and other related costs |
|
— |
|
|
(13,719 |
) |
|
— |
|
|||
Loss on disposal of businesses |
|
— |
|
|
(2,134 |
) |
|
(2,134 |
) |
|||
Gain on asset sales |
|
654 |
|
|
135 |
|
|
4,870 |
|
|||
Operating income (loss) |
|
17,804 |
|
|
(27,161 |
) |
|
18,764 |
|
|||
Other income, net |
|
9,312 |
|
|
7,167 |
|
|
15,441 |
|
|||
Interest income |
|
1,505 |
|
|
990 |
|
|
1,138 |
|
|||
Interest expense |
|
(17,095 |
) |
|
(9,341 |
) |
|
(11,431 |
) |
|||
Income (loss) before income taxes and equity earnings |
|
11,526 |
|
|
(28,345 |
) |
|
23,912 |
|
|||
Income tax benefit |
|
34,778 |
|
|
3,401 |
|
|
4,091 |
|
|||
Equity method earnings |
|
300 |
|
|
3,381 |
|
|
7,901 |
|
|||
Net income (loss) |
|
46,604 |
|
|
(21,563 |
) |
|
35,904 |
|
|||
Less: Net income attributable to noncontrolling interests |
|
(6,767 |
) |
|
(6,953 |
) |
|
(7,270 |
) |
|||
Net income (loss) attributable to |
$ |
39,837 |
|
$ |
(28,516 |
) |
$ |
28,634 |
|
|||
|
|
|
|
|||||||||
Net income (loss) per share attributable to |
$ |
0.42 |
|
$ |
(0.35 |
) |
$ |
0.30 |
|
|||
Net income (loss) per share attributable to |
$ |
0.42 |
|
$ |
(0.35 |
) |
$ |
0.30 |
|
|||
Weighted average shares outstanding – basic |
|
94,891 |
|
|
82,166 |
|
|
94,878 |
|
|||
Weighted average shares outstanding – diluted |
|
94,908 |
|
|
82,166 |
|
|
95,030 |
|
Nine Months Ended |
||||||||||||
2022 |
2021 |
2021 |
||||||||||
|
|
Pro-forma |
||||||||||
( |
||||||||||||
Revenues, net |
$ |
6,872,655 |
|
$ |
4,202,922 |
|
$ |
7,034,192 |
|
|||
Cost of sales |
|
(6,435,233 |
) |
|
(3,917,484 |
) |
|
(6,449,848 |
) |
|||
Gross profit |
|
437,422 |
|
|
285,438 |
|
|
584,344 |
|
|||
Selling, marketing, general and administrative expenses |
|
(364,043 |
) |
|
(249,593 |
) |
|
(383,338 |
) |
|||
Merger, transaction and other related costs |
|
— |
|
|
(28,814 |
) |
|
— |
|
|||
Gain (loss) on disposal of businesses |
|
242 |
|
|
(595 |
) |
|
(595 |
) |
|||
Gain on asset sales |
|
9,075 |
|
|
262 |
|
|
12,381 |
|
|||
Operating income |
|
82,696 |
|
|
6,698 |
|
|
212,792 |
|
|||
Other income, net |
|
20,434 |
|
|
7,867 |
|
|
19,812 |
|
|||
Interest income |
|
4,596 |
|
|
1,826 |
|
|
3,209 |
|
|||
Interest expense |
|
(41,724 |
) |
|
(14,187 |
) |
|
(34,385 |
) |
|||
Income before income taxes and equity earnings |
|
66,002 |
|
|
2,204 |
|
|
201,428 |
|
|||
Income tax benefit (expense) |
|
28,355 |
|
|
(4,838 |
) |
|
(41,971 |
) |
|||
Equity method earnings |
|
4,028 |
|
|
44,018 |
|
|
17,597 |
|
|||
Net income |
|
98,385 |
|
|
41,384 |
|
|
177,054 |
|
|||
Less: Net income attributable to noncontrolling interests |
|
(18,670 |
) |
|
(19,352 |
) |
|
(21,225 |
) |
|||
Net income attributable to |
$ |
79,715 |
|
$ |
22,032 |
|
$ |
155,829 |
|
|||
|
|
|
|
|||||||||
Net income per share attributable to |
$ |
0.84 |
|
$ |
0.34 |
|
$ |
1.64 |
|
|||
Net income per share attributable to |
$ |
0.84 |
|
$ |
0.34 |
|
$ |
1.64 |
|
|||
Weighted average shares outstanding – basic |
|
94,882 |
|
|
64,516 |
|
|
94,878 |
|
|||
Weighted average shares outstanding – diluted |
94,915 |
64,723 |
95,030 |
Consolidated Balance Sheets - Unaudited |
||||||||
2022 |
2021 |
|||||||
ASSETS |
( |
|||||||
Cash and cash equivalents |
$ |
221,476 |
|
$ |
250,561 |
|
||
Short-term investments |
|
5,090 |
|
|
6,115 |
|
||
Trade receivables, net of allowances for credit losses of |
|
567,931 |
|
|
719,114 |
|
||
Grower advance receivables, net of allowances for credit losses of |
|
149,086 |
|
|
72,350 |
|
||
Other receivables, net of allowances for credit losses of |
|
156,087 |
|
|
125,908 |
|
||
Inventories, net of allowances of |
|
451,926 |
|
|
410,737 |
|
||
Prepaid expenses |
|
56,134 |
|
|
45,339 |
|
||
Other current assets |
|
27,694 |
|
|
11,011 |
|
||
Assets held-for-sale |
|
80 |
|
|
200 |
|
||
Total current assets |
|
1,635,504 |
|
|
1,641,335 |
|
||
Long-term investments |
|
17,347 |
|
|
23,433 |
|
||
Investments in unconsolidated affiliates |
|
115,952 |
|
|
128,407 |
|
||
Actively marketed property |
|
36,842 |
|
|
50,364 |
|
||
Property, plant and equipment, net of accumulated depreciation of |
|
1,323,421 |
|
|
1,430,850 |
|
||
Operating lease right-of-use assets |
|
358,699 |
|
|
368,632 |
|
||
|
|
487,524 |
|
|
511,333 |
|
||
DOLE brand |
|
306,280 |
|
|
306,280 |
|
||
Other intangible assets, net of accumulated amortization of |
|
52,103 |
|
|
62,046 |
|
||
Other assets |
|
147,017 |
|
|
98,917 |
|
||
Deferred income tax assets |
|
47,179 |
|
|
46,371 |
|
||
Total assets |
$ |
4,527,868 |
|
$ |
4,667,968 |
|
||
LIABILITIES AND EQUITY |
|
|
||||||
Accounts payable |
$ |
657,116 |
|
$ |
696,766 |
|
||
Income taxes payable |
|
17,190 |
|
|
10,316 |
|
||
Accrued liabilities |
|
474,865 |
|
|
464,931 |
|
||
Bank overdrafts |
|
20,284 |
|
|
9,395 |
|
||
Notes payable and current portion of long-term debt, net |
|
78,984 |
|
|
51,785 |
|
||
Current maturities of operating leases |
|
86,563 |
|
|
73,046 |
|
||
Other tax |
|
27,296 |
|
|
35,212 |
|
||
Contingent consideration |
|
1,700 |
|
|
2,958 |
|
||
Pension and postretirement benefits |
|
16,873 |
|
|
17,664 |
|
||
Dividends payable and other current liabilities |
|
19,313 |
|
|
9,078 |
|
||
Total current liabilities |
|
1,400,184 |
|
|
1,371,151 |
|
||
Long-term debt, net |
|
1,208,152 |
|
|
1,297,808 |
|
||
Operating leases, less current maturities |
|
278,429 |
|
|
305,714 |
|
||
Deferred income tax liabilities |
|
150,374 |
|
|
145,689 |
|
||
Income tax payable, less current portion |
|
30,501 |
|
|
40,439 |
|
||
Contingent consideration, less current portion |
|
4,729 |
|
|
4,302 |
|
||
Pension and postretirement benefits, less current portion |
|
135,790 |
|
|
152,149 |
|
||
Other long-term liabilities |
|
62,507 |
|
|
105,310 |
|
||
Total liabilities |
$ |
3,270,666 |
|
$ |
3,422,562 |
|
||
Commitments and contingent liabilities (See Note 16) |
|
|
||||||
Redeemable noncontrolling interests |
|
31,770 |
|
|
32,776 |
|
||
Stockholders’ equity: |
|
|
||||||
Common stock — |
|
949 |
|
|
950 |
|
||
Additional paid-in capital |
|
793,521 |
|
|
792,223 |
|
||
Retained earnings |
|
470,125 |
|
|
413,335 |
|
||
Accumulated other comprehensive loss |
|
(154,137 |
) |
|
(125,919 |
) |
||
Total equity attributable to |
|
1,110,458 |
|
|
1,080,589 |
|
||
Equity attributable to noncontrolling interests |
|
114,974 |
|
|
132,041 |
|
||
Total equity |
|
1,225,432 |
|
|
1,212,630 |
|
||
Total liabilities, redeemable noncontrolling interests and equity |
$ |
4,527,868 |
|
$ |
4,667,968 |
|
Consolidated Statements of Cash Flows - Unaudited |
||||||||
Nine Months Ended |
||||||||
2022 |
2021 |
|||||||
Operating Activities |
( |
|||||||
Net income |
$ |
98,385 |
|
$ |
41,384 |
|
||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
|
|
||||||
Depreciation and amortization |
|
97,827 |
|
|
42,537 |
|
||
Incremental charges on purchase accounting valuation of biological assets and inventory |
|
40,464 |
|
|
29,180 |
|
||
Asset write-offs and net gain on sale of assets |
|
(9,075 |
) |
|
— |
|
||
Net gain on financial instruments |
|
(1,482 |
) |
|
(2,795 |
) |
||
Stock-based compensation expense |
|
3,118 |
|
|
— |
|
||
Equity method earnings |
|
(4,028 |
) |
|
(36,998 |
) |
||
Net (gain) loss on disposal of businesses |
|
(242 |
) |
|
595 |
|
||
Amortization of debt discounts and debt issuance costs |
|
4,546 |
|
|
904 |
|
||
(Benefit) provision for deferred income taxes and other tax-related liabilities |
|
(49,823 |
) |
|
221 |
|
||
Pension and other postretirement benefit plan benefit cost |
|
482 |
|
|
232 |
|
||
Fair value movement on contingent consideration |
|
64 |
|
|
1,130 |
|
||
Dividends received from equity method investees |
|
7,632 |
|
|
10,715 |
|
||
Net gain on acquisitions and disposals of equity method investments |
|
— |
|
|
(7,020 |
) |
||
Other |
|
(617 |
) |
|
859 |
|
||
Changes in operating assets and liabilities: |
|
|
||||||
Receivables, net of allowances |
|
(35,896 |
) |
|
(120,091 |
) |
||
Inventories |
|
(60,647 |
) |
|
(50,454 |
) |
||
Operating lease liabilities |
|
3,703 |
|
|
6,055 |
|
||
Accrued and other current and long-term liabilities |
|
27,144 |
|
|
64,286 |
|
||
Cash flow provided by (used in) operating activities |
|
121,555 |
|
|
(19,260 |
) |
||
Investing Activities |
|
|
||||||
Sales of assets |
|
27,764 |
|
|
13,869 |
|
||
Capital expenditures |
|
(66,582 |
) |
|
(32,790 |
) |
||
Acquisitions, net of cash acquired |
|
(4,886 |
) |
|
99,733 |
|
||
Insurance proceeds |
|
2,278 |
|
|
10,217 |
|
||
Purchases of investments |
|
(414 |
) |
|
(1,186 |
) |
||
Investments in unconsolidated affiliates |
|
(801 |
) |
|
(909 |
) |
||
Proceeds from sale of investments in unconsolidated affiliates |
|
— |
|
|
10,607 |
|
||
Other |
|
25 |
|
|
(1,343 |
) |
||
Cash flow (used in) provided by investing activities |
|
(42,616 |
) |
|
98,198 |
|
||
Financing Activities |
|
|
||||||
Proceeds from borrowings and overdrafts |
|
1,008,423 |
|
|
1,714,671 |
|
||
Repayments on borrowings and overdrafts |
|
(1,050,928 |
) |
|
(2,056,485 |
) |
||
Payment of debt issuance costs |
|
(265 |
) |
|
(21,108 |
) |
||
Dividends paid to shareholders |
|
(22,770 |
) |
|
(17,092 |
) |
||
Dividends paid to noncontrolling interests |
|
(20,981 |
) |
|
(20,444 |
) |
||
Payments of contingent consideration |
|
(2,451 |
) |
|
— |
|
||
Proceeds from exercise of share options |
|
— |
|
|
8,012 |
|
||
Proceeds received from issuance of common stock in initial public offering, net of issuance costs |
|
— |
|
|
398,876 |
|
||
Cash flow (used in) provided by financing activities |
|
(88,972 |
) |
|
6,430 |
|
||
Effect of foreign currency exchange rate changes on cash |
|
(19,052 |
) |
|
(11,657 |
) |
||
(Decrease) increase in cash and cash equivalents |
|
(29,085 |
) |
|
73,711 |
|
||
Cash and cash equivalents at beginning of period |
|
250,561 |
|
|
160,503 |
|
||
Cash and cash equivalents at end of period |
$ |
221,476 |
|
$ |
234,214 |
|
Reconciliation from Net Income to Adjusted EBITDA - Unaudited
The following information is provided to give quantitative information related to items impacting comparability. Refer to the 'Non-GAAP Financial Measures' section of this document for additional detail on each item.
Three Months Ended |
||||||||||||
2022 |
2021 |
2021 |
||||||||||
Pro-forma |
||||||||||||
( |
||||||||||||
Net income (Reported GAAP) |
$ |
46,604 |
|
$ |
(21,563 |
) |
$ |
35,904 |
|
|||
Income tax benefit |
|
(34,778 |
) |
|
(3,401 |
) |
|
(4,091 |
) |
|||
Interest expense |
|
17,095 |
|
|
9,341 |
|
|
11,431 |
|
|||
Merger, transaction and other related costs |
|
— |
|
|
13,719 |
|
|
— |
|
|||
Mark to market (gains) losses |
|
2,310 |
|
|
(2,921 |
) |
|
(2,572 |
) |
|||
(Gain) on asset sales |
|
(530 |
) |
|
— |
|
|
(4,610 |
) |
|||
Produce recalls |
|
(442 |
) |
|
— |
|
|
— |
|
|||
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
|
5,520 |
29,180 |
|
— |
|||||||
Other items4 |
|
(532 |
) |
|
(1,201 |
) |
|
(13,133 |
) |
|||
Adjustments from equity method investments |
|
1,602 |
|
|
2,357 |
|
|
1,164 |
|
|||
Adjusted EBIT (Non-GAAP) |
|
36,849 |
|
|
25,511 |
|
|
24,093 |
|
|||
Depreciation |
|
30,424 |
|
|
21,103 |
|
|
29,368 |
|
|||
Amortization of intangible assets |
|
2,633 |
|
|
2,649 |
|
|
2,664 |
|
|||
Depreciation and amortization adjustments from equity method investments |
|
3,074 |
|
|
5,675 |
|
|
1,925 |
|
|||
Adjusted EBITDA (Non-GAAP) |
$ |
72,980 |
|
$ |
54,938 |
|
$ |
58,050 |
|
__________________________________________ | ||
4 |
For the three months ended |
Nine Months Ended |
||||||||||||
2022 |
2021 |
2021 |
||||||||||
|
|
Pro-forma |
||||||||||
( |
||||||||||||
Net income (Reported GAAP) |
$ |
98,385 |
|
$ |
41,384 |
|
$ |
177,054 |
|
|||
Income tax (benefit) expense |
|
(28,355 |
) |
|
4,838 |
|
|
41,971 |
|
|||
Interest expense |
|
41,724 |
|
|
14,187 |
|
|
34,385 |
|
|||
Merger, transaction and other related costs |
|
— |
|
|
28,814 |
|
|
— |
|
|||
Mark to market (gains) |
|
(5,819 |
) |
|
(1,856 |
) |
|
(3,835 |
) |
|||
(Gain) on asset sales |
|
(8,346 |
) |
|
— |
|
|
(9,292 |
) |
|||
Produce recalls |
|
15,809 |
|
|
— |
|
|
— |
|
|||
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
|
40,464 |
29,180 |
— |
||||||||
Other items5 |
|
(1,283 |
) |
|
(6,441 |
) |
|
(13,557 |
) |
|||
Adjustments from equity method investments |
|
4,926 |
|
|
45,406 |
|
|
4,287 |
|
|||
Adjusted EBIT (Non-GAAP) |
|
157,505 |
|
|
155,512 |
|
|
231,013 |
|
|||
Depreciation |
|
89,579 |
|
|
34,316 |
|
|
86,681 |
|
|||
Amortization of intangible assets |
|
8,248 |
|
|
8,221 |
|
|
8,236 |
|
|||
Depreciation and amortization adjustments from equity method investments |
|
7,998 |
|
|
30,966 |
|
|
6,539 |
|
|||
Adjusted EBITDA (Non-GAAP) |
$ |
263,330 |
|
$ |
229,015 |
|
$ |
332,469 |
|
__________________________________________ | ||
5 |
For the nine months ended |
Reconciliation from Net Income attributable to
The following information is provided to give quantitative information related to items impacting comparability. Refer to the 'Non-GAAP Financial Measures' section of this document for additional detail on each item. Refer to the Appendix for supplementary detail.
Three Months Ended |
||||||||||||
2022 |
2021 |
2021 |
||||||||||
Pro-forma |
||||||||||||
( |
||||||||||||
Net income (loss) attributable to |
$ |
39,837 |
|
$ |
(28,516 |
) |
$ |
28,634 |
|
|||
Adjustments: |
|
|
|
|||||||||
Amortization of intangible assets |
|
2,633 |
|
|
2,649 |
|
|
2,664 |
|
|||
Merger, transaction and other related costs |
|
— |
|
|
13,719 |
|
|
— |
|
|||
Mark to market (gains) losses |
|
2,310 |
|
|
(2,921 |
) |
|
(2,572 |
) |
|||
(Gain) on asset sales |
|
(530 |
) |
|
— |
|
|
(4,610 |
) |
|||
Produce recalls |
|
(442 |
) |
|
— |
|
|
— |
|
|||
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
5,520 |
29,180 |
|
— |
||||||||
Other items6 |
|
(532 |
) |
|
(1,201 |
) |
|
(13,133 |
) |
|||
Adjustments from equity method investments |
|
628 |
|
|
(721 |
) |
|
972 |
|
|||
Income tax on items above and discrete tax items |
|
(35,017 |
) |
|
(5,345 |
) |
|
(8,621 |
) |
|||
NCI impact on items above |
|
(878 |
) |
|
(885 |
) |
|
(927 |
) |
|||
Adjusted Net Income for Adjusted EPS calculation (Non-GAAP) |
$ |
13,529 |
|
$ |
5,959 |
|
$ |
2,407 |
|
|||
Adjusted earnings per share – basic (Non-GAAP) |
$ |
0.14 |
|
$ |
0.07 |
|
$ |
0.03 |
|
|||
Adjusted earnings per share – diluted (Non-GAAP) |
$ |
0.14 |
|
$ |
0.07 |
|
$ |
0.03 |
|
|||
Weighted average shares outstanding – basic |
|
94,891 |
|
|
82,166 |
|
|
94,878 |
|
|||
Weighted average shares outstanding – diluted |
|
94,908 |
|
|
82,166 |
|
|
95,030 |
|
__________________________________________ | ||
6 |
For the three months ended |
Nine Months Ended |
||||||||||||
2022 |
2021 |
2021 |
||||||||||
|
|
Pro-forma |
||||||||||
( |
||||||||||||
Net income attributable to |
$ |
79,715 |
|
$ |
22,032 |
|
$ |
155,829 |
|
|||
Adjustments: |
|
|
|
|||||||||
Amortization of intangible assets |
|
8,248 |
|
|
8,221 |
|
|
8,236 |
|
|||
Merger, transaction and other related costs |
|
— |
|
|
28,814 |
|
|
— |
|
|||
Mark to market (gains) |
|
(5,819 |
) |
|
(1,856 |
) |
|
(3,835 |
) |
|||
(Gain) on asset sales |
|
(8,346 |
) |
|
— |
|
|
(9,292 |
) |
|||
Produce recalls |
|
15,809 |
|
|
— |
|
|
— |
|
|||
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
40,464 |
29,180 |
— |
|||||||||
Other items7 |
|
(1,283 |
) |
|
(6,441 |
) |
|
(13,557 |
) |
|||
Adjustments from equity method investments |
|
1,918 |
|
|
703 |
|
|
2,462 |
|
|||
Income tax on items above and discrete tax items |
|
(45,389 |
) |
|
(4,807 |
) |
|
(9,390 |
) |
|||
NCI impact on items above |
|
(2,289 |
) |
|
(2,724 |
) |
|
(2,766 |
) |
|||
Adjusted Net Income for Adjusted EPS calculation (Non-GAAP) |
$ |
83,028 |
|
$ |
73,122 |
|
$ |
127,687 |
|
|||
Adjusted earnings per share – basic (Non-GAAP) |
$ |
0.88 |
|
$ |
1.13 |
|
$ |
1.35 |
|
|||
Adjusted earnings per share – diluted (Non-GAAP) |
$ |
0.87 |
|
$ |
1.13 |
|
$ |
1.34 |
|
|||
Weighted average shares outstanding – basic |
|
94,882 |
|
|
64,516 |
|
|
94,878 |
|
|||
Weighted average shares outstanding – diluted |
|
94,915 |
|
|
64,723 |
|
|
95,030 |
|
__________________________________________ | ||
7 |
For the nine months ended |
Net Debt Reconciliation
Net Debt is the primary measure used by management to analyze the Company’s capital structure. Net Debt is a non- GAAP financial measure, calculated as cash and cash equivalents, less current and long-term debt. It also excludes debt discounts and debt issuance costs. The calculation of Net Debt as of
|
||||
( |
||||
Cash and cash equivalents (Reported GAAP) |
$ |
221,476 |
|
|
Debt (Reported GAAP): |
||||
Long-term debt, net |
|
(1,208,152 |
) |
|
Current maturities |
|
(78,984 |
) |
|
Bank overdrafts |
|
(20,284 |
) |
|
Total debt, net |
|
(1,307,420 |
) |
|
Less: Debt discounts and debt issuance costs (Reported GAAP) |
|
(18,724 |
) |
|
Total gross debt |
|
(1,326,144 |
) |
|
Net Debt (Non-GAAP) |
$ |
(1,104,668 |
) |
Non-GAAP Financial Measures
Dole plc’s results are determined in accordance with
In addition to its results under
Adjusted EBIT is calculated from GAAP net income by: (1) subtracting the income tax expense or adding the income tax benefit; (2) subtracting interest expense; (3) subtracting mark to market losses or adding mark to market gains related to unrealized impacts from derivative instruments and foreign currency denominated borrowings, realized impacts on noncash settled foreign currency denominated borrowings, net foreign currency impacts on liquidated entities and fair value movements on contingent consideration; (4) other items which are separately stated based on materiality, which include subtracting merger, transaction and other related costs, subtracting incremental costs for produce recalls, adding or subtracting asset write-downs, net of insurance proceeds, adding the gain or subtracting the loss on the disposal of business interests, subtracting the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole, subtracting impairment charges on property, plant and equipment, adding the fair value gain or subtracting the fair value loss on the acquisition of investments previously accounted for under the equity method, subtracting the gain or adding the loss on the sale of investments accounted for under the equity method, adding the gain or subtracting the loss on asset sales for assets held-for-sale and actively marketed property and subtracting restructuring charges and costs for legal matters not in the ordinary course of business; and (5) adjustments from equity method investments, which includes the Company’s share of these items within equity method earnings.
Adjusted EBITDA is calculated from GAAP net income by: (1) subtracting the income tax expense or adding the income tax benefit; (2) subtracting interest expense; (3) subtracting depreciation charges; (4) subtracting amortization charges; (5) subtracting mark to market losses or adding mark to market gains related to unrealized impacts from derivative instruments and foreign currency denominated borrowings, realized impacts on noncash settled foreign currency denominated borrowings, net foreign currency impacts on liquidated entities and fair value movements on contingent consideration; (6) other items which are separately stated based on materiality, which include subtracting merger, transaction and other related costs, subtracting incremental costs for produce recalls, adding or subtracting asset write-downs, net of insurance proceeds, adding the gain or subtracting the loss on the disposal of business interests, subtracting the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole, subtracting impairment charges on property, plant and equipment, adding the fair value gain or subtracting the fair value loss on the acquisition of investments previously accounted for under the equity method, subtracting the gain or adding the loss on the sale of investments accounted for under the equity method, adding the gain or subtracting the loss on asset sales for assets held-for-sale and actively marketed property and subtracting restructuring charges and costs for legal matters not in the ordinary course of business; and (7) adjustments from equity method investments, which includes the Company’s share of these items within equity method earnings.
Adjusted Net Income is calculated from GAAP net income attributable to
Adjusted Earnings per Share is calculated from Adjusted Net Income divided by diluted weighted average number of shares in the applicable period.
Adjusted Effective tax rate is calculated from the GAAP effective tax rate by: (1) adjusting the tax impact for each adjustment from GAAP net income attributable to
Net Debt is a non-GAAP financial measure, calculated as GAAP cash and cash equivalents, less GAAP current and long-term debt. It also excludes GAAP debt discounts and debt issuance costs.
Pro-forma EBIT is calculated from pro-forma net income by adding pro-forma interest expense and adding the pro-forma income tax expense or subtracting the pro-forma income tax benefit, as well as including the following pro-forma adjustments: (1) subtracting mark to market losses or adding mark to market gains related to unrealized impacts from derivative instruments and foreign currency denominated borrowings, realized
impacts on noncash settled foreign currency denominated borrowings, net foreign currency impacts on liquidated entities and fair value movements on contingent consideration; (2) other items which are separately stated based on materiality, which include subtracting merger, transaction and other related costs, subtracting incremental costs for produce recalls, adding or subtracting asset write-downs, net of insurance proceeds, adding the gain or subtracting the loss on the disposal of business interests, subtracting the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole, subtracting impairment charges on property, plant and equipment, adding the fair value gain or subtracting the fair value loss on the acquisition of investments previously accounted for under the equity method, subtracting the gain or adding the loss on the sale of investments accounted for under the equity method, adding the gain or subtracting the loss on asset sales for assets held-for-sale and actively marketed property and subtracting restructuring charges and costs for legal matters not in the ordinary course of business; and (3) adjustments from equity method investments, which includes the Company’s share of these items within equity method earnings.
Pro-forma Adjusted EBITDA is calculated from pro-forma EBIT by including the following pro-forma adjustments: (1) adding depreciation charges; and (2) adding amortization charges. It also includes the effect of the Company’s share of these listed items within investments accounted for under the equity method.
Pro-forma Adjusted Net Income is calculated from pro-forma net income attributable to
Pro-forma Adjusted Earnings per Share is calculated from pro-forma Adjusted Net Income divided by diluted weighted average number of shares in the applicable period.
Adjusted EBIT, pro-forma EBIT, Adjusted EBITDA, pro-forma Adjusted EBITDA, Adjusted Net Income, pro-forma Adjusted Net Income, Adjusted EPS, Adjusted Effective tax rate, Net Debt and pro-forma Adjusted EPS are not measurements of
- They do not reflect Dole plc’s cash expenditures, or future requirements, for capital expenditures or contractual commitments;
- They do not reflect changes in, or cash requirements for, Dole plc’s working capital needs;
- They do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on Dole plc’s debt; and
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and these non-GAAP financial measures do not reflect cash requirements for such replacements.
Because of these limitations, pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS should not be considered as measures of discretionary cash available to
Further, pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS as used herein may not be calculated in a similar manner to, and are therefore not necessarily comparable with, similarly titled measures of other companies. However, we have included pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS herein because Dole plc’s management believes that pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS are useful performance measures.
Dole is not able to provide a reconciliation for projected FY'22 Adjusted EBITDA and Adjusted Effective tax rate without undertaking unreasonable efforts.
Pro-forma Methodology
The methodology used to prepare the unaudited pro-forma consolidated financial statements for
-
All associated transaction costs reflected on
January 1, 2020 . As such, no transaction costs are included within the pro-forma numbers discussed below. -
Effective tax rate of
25% for the nine months endedSeptember 30, 2021 . -
Applying the results of the Purchase Price Allocation (“PPA”) exercise, acquisition accounting and debt refinancing to
January 1, 2020 :-
Q3 2021 year to date pro-forma results reflect a reduction in the depreciation charge of
. This is a function of the asset values increasing as a result of the PPA exercise offset by an increase in the estimated useful lives of the assets.$3.0 million - The interest expense for Q3 2021 reflects the outcome of the refinancing.
-
Q3 2021 year to date pro-forma results reflect a reduction in the depreciation charge of
-
TP’s pickup of its
45.0% share of DFC’s net income has been eliminated. - EPS is calculated using shares in issue following the IPO and additional share issuances.
-
There is a year to date adjustment in Q3 2021 of
to reflect estimated ongoing incremental public company costs of$9.7 million annualized.$14.0 million
See reconciliation of pro-forma results for the three and six months ended
Pro-forma Reconciliation (Unaudited) – for the three months ended
TP |
DFC |
|
FV &
|
Transaction
|
Ongoing
|
Debt
|
Tax
|
Pro-forma
|
||||||||||||||||||||
( |
||||||||||||||||||||||||||||
Revenues, net |
$ |
1,186,965 |
|
1,134,459 |
|
2,321,424 |
|
(15,387 |
) |
— |
— |
|
— |
|
— |
|
$ |
2,306,037 |
|
|||||||||
Cost of sales |
|
(1,092,529 |
) |
(1,092,073 |
) |
(2,184,602 |
) |
16,291 |
|
— |
— |
|
— |
|
— |
|
|
(2,168,311 |
) |
|||||||||
Gross profit |
|
94,436 |
|
42,386 |
|
136,822 |
|
904 |
|
— |
— |
|
— |
|
— |
|
|
137,726 |
|
|||||||||
Selling, marketing and general and administrative expenses |
|
(75,236 |
) |
(50,812 |
) |
(126,048 |
) |
5 |
|
4,045 |
300 |
|
— |
|
— |
|
|
(121,698 |
) |
|||||||||
Merger, transaction, and other related costs |
|
(7,558 |
) |
1,798 |
|
(5,760 |
) |
— |
|
5,760 |
— |
|
— |
|
— |
|
|
— |
|
|||||||||
Gain on disposal of businesses |
|
(2,134 |
) |
— |
|
(2,134 |
) |
— |
|
— |
— |
|
— |
|
— |
|
|
(2,134 |
) |
|||||||||
Gain on asset sales |
|
(127 |
) |
4,997 |
|
4,870 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
4,870 |
|
|||||||||
Operating income (loss) |
|
9,381 |
|
(1,631 |
) |
7,750 |
|
909 |
|
9,805 |
300 |
|
— |
|
— |
|
|
18,764 |
|
|||||||||
Other income (expense), net |
|
2,085 |
|
12,384 |
|
14,469 |
|
972 |
|
— |
— |
|
— |
|
— |
|
|
15,441 |
|
|||||||||
Interest income |
|
496 |
|
642 |
|
1,138 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
1,138 |
|
|||||||||
Interest expense |
|
(6,546 |
) |
(8,841 |
) |
(15,387 |
) |
— |
|
— |
— |
|
3,956 |
|
— |
|
|
(11,431 |
) |
|||||||||
Income (loss) before income taxes and equity earnings |
|
5,416 |
|
2,554 |
|
7,970 |
|
1,881 |
|
9,805 |
300 |
3,956 |
|
— |
|
|
23,912 |
|
||||||||||
Income tax (expense) benefit |
|
(5,823 |
) |
12,387 |
|
6,564 |
|
277 |
|
— |
(94 |
) |
(1,245 |
) |
(1,411 |
) |
|
4,091 |
|
|||||||||
Equity in net earnings of investments accounted for under the equity method |
|
3,720 |
|
(378 |
) |
3,342 |
4,559 |
— |
— |
— |
— |
7,901 |
||||||||||||||||
Net income (loss) |
|
3,313 |
|
14,563 |
|
17,876 |
|
6,717 |
|
9,805 |
206 |
|
2,711 |
|
(1,411 |
) |
|
35,904 |
|
|||||||||
Less: Net income attributable to noncontrolling interests |
(6,570 |
) |
(700 |
) |
(7,270 |
) |
— |
— |
— |
— |
|
— |
(7,270 |
) |
||||||||||||||
Net income (loss) attributable to |
$ |
(3,257 |
) |
13,863 |
|
10,606 |
|
6,717 |
|
9,805 |
206 |
|
2,711 |
|
(1,411 |
) |
$ |
28,634 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Earnings per share: |
||||||||||||||||||||||||||||
Net income per share - basic |
|
|
|
|
|
|
|
$ |
0.30 |
|
||||||||||||||||||
Net income per share - diluted |
|
|
|
|
|
|
|
$ |
0.30 |
|
||||||||||||||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Basic |
|
|
|
|
|
|
|
|
|
94,878 |
|
|||||||||||||||||
Diluted |
|
|
|
|
|
|
|
|
|
95,030 |
|
Pro-forma Reconciliation (Unaudited) – for the nine months ended
TP |
DFC |
|
FV &
|
Transaction
|
Ongoing
|
Debt
|
Tax
|
Pro-forma
|
||||||||||||||||||||
( |
||||||||||||||||||||||||||||
Revenues, net |
$ |
3,447,702 |
|
3,639,104 |
|
7,086,806 |
|
(52,614 |
) |
— |
— |
|
— |
|
— |
|
$ |
7,034,192 |
|
|||||||||
Cost of sales |
|
(3,166,598 |
) |
(3,338,768 |
) |
(6,505,366 |
) |
55,518 |
|
— |
— |
|
— |
|
— |
|
|
(6,449,848 |
) |
|||||||||
Gross profit |
|
281,104 |
|
300,336 |
|
581,440 |
|
2,904 |
|
— |
— |
|
— |
|
— |
|
|
584,344 |
|
|||||||||
Selling, marketing and general and administrative expenses |
|
(214,616 |
) |
(163,022 |
) |
(377,638 |
) |
5 |
|
4,045 |
(9,750 |
) |
— |
|
— |
|
|
(383,338 |
) |
|||||||||
Merger, transaction, and other related costs |
|
(22,653 |
) |
— |
|
(22,653 |
) |
— |
|
22,653 |
— |
|
— |
|
— |
|
|
— |
|
|||||||||
Gain on disposal of businesses |
|
(595 |
) |
— |
|
(595 |
) |
— |
|
— |
— |
|
— |
|
— |
|
|
(595 |
) |
|||||||||
Gain on asset sales |
|
— |
|
12,381 |
|
12,381 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
12,381 |
|
|||||||||
Operating income (loss) |
|
43,240 |
|
149,695 |
|
192,935 |
|
2,909 |
|
26,698 |
(9,750 |
) |
— |
|
— |
|
|
212,792 |
|
|||||||||
Other income (expense), net |
|
2,785 |
|
16,055 |
|
18,840 |
|
972 |
|
— |
— |
|
— |
|
— |
|
|
19,812 |
|
|||||||||
Interest income |
|
1,332 |
|
1,877 |
|
3,209 |
|
— |
|
— |
— |
|
— |
|
— |
|
|
3,209 |
|
|||||||||
Interest expense |
|
(11,392 |
) |
(42,465 |
) |
(53,857 |
) |
— |
|
— |
— |
|
19,472 |
|
— |
|
|
(34,385 |
) |
|||||||||
Income (loss) before income taxes and equity earnings |
|
35,965 |
|
125,162 |
|
161,127 |
|
3,881 |
|
26,698 |
(9,750 |
) |
19,472 |
|
— |
|
|
201,428 |
|
|||||||||
Income tax (expense) benefit |
|
(14,062 |
) |
(19,299 |
) |
(33,361 |
) |
277 |
|
— |
3,066 |
|
(6,123 |
) |
(5,830 |
) |
|
(41,971 |
) |
|||||||||
Equity in net earnings of investments accounted for under the equity method |
|
44,357 |
|
(313 |
) |
44,044 |
|
(26,447 |
) |
— |
— |
|
— |
|
— |
|
|
17,597 |
|
|||||||||
Net income (loss) |
|
66,260 |
|
105,550 |
|
171,810 |
|
(22,289 |
) |
26,698 |
(6,684 |
) |
13,349 |
|
(5,830 |
) |
|
177,054 |
|
|||||||||
Less: Net income attributable to noncontrolling interests |
|
(18,969 |
) |
(2,256 |
) |
(21,225 |
) |
— |
|
— |
— |
|
— |
|
— |
|
|
(21,225 |
) |
|||||||||
Net income (loss) attributable to |
$ |
47,291 |
|
103,294 |
|
150,585 |
|
(22,289 |
) |
26,698 |
(6,684 |
) |
13,349 |
|
(5,830 |
) |
$ |
155,829 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Earnings per share: |
||||||||||||||||||||||||||||
Net income per share - basic |
|
|
|
|
|
|
|
$ |
1.64 |
|
||||||||||||||||||
Net income per share - diluted |
|
|
|
|
|
|
|
$ |
1.64 |
|
||||||||||||||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Basic |
|
|
|
|
|
|
|
|
|
94,878 |
|
|||||||||||||||||
Diluted |
|
|
|
|
|
|
|
|
|
95,030 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005356/en/
Investor Contact:
joregan@totalproduce.com
+353 1 887 2794
Media Contact:
brian.bell@ogilvy.com
+353 87 2436 130
Source:
FAQ
What were Dole's Q3 2022 earnings results?
How did Dole's revenue change compared to last year?
What is the outlook for Dole in FY 2022?
What factors affected Dole's financial performance?